Anti-C5 antibodies having improved pharmacokinetics
US9803007B1 · kind B1 · utility
10Cited by
47References
7Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 20, 2017 |
| Grant date | Oct 31, 2017 |
| Priority date | — |
| Expiry date | Apr 20, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/94
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The disclosure provides antibodies that are useful for, among other things, inhibiting terminal complement (e.g., the assembly and/or activity of the C5b-9 TCC) and C5a anaphylatoxin-mediated inflammation and, thus, treating complement-associated disorders. The antibodies have a number of improved properties relative to eculizumab, including, e.g., increased serum half-life in a human.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.